Skip to content
Non-Invasive Serum Lipidomic Approach To Discriminate Non-Alcoholic Steatohepatitis (NASH) In Multiethnic Patients With Type 2 Diabetes Mellitus
Despite the growing prevalence of NASH, there are currently no approved treatments for the disease beyond liver transplant. The constellation of risk factors for NASH has generated a multitude of targets and there is an obvious need to bring promising treatments through clinical trials and to patients quickly.
Publication – Non-Invasive Serum Lipidomic Approach To Discriminate Non-Alcoholic Steatohepatitis In Multiethnic Patients With Type 2 Diabetes Mellitus
Reach out to our experts and discover how we can help you advance your research
Contact Us